November 11, 2025 — ClinChoice is proud to announce the successful completion and approval of its ISO 9001:2015 and ISO 14155:2020 Re-Certification by TÜV NORD.
The audit, conducted between 13 October 2025 and 4 November 2025, spanned our United States, Italy, Philippines, Armenia, and India delivery sites. The comprehensive assessment involved nine auditors and approximately 20 man-days of rigorous evaluation.
This achievement marks a significant milestone in our quality journey — the consolidation of our Quality Management System (QMS) certification from multiple regional certificates into a single Global Certificate. This unification strengthens our global quality framework, ensuring greater consistency, efficiency, and alignment across our operations worldwide.
“Our consolidated global certification reflects more than compliance — it represents our leadership in harmonizing quality practices across continents. It strengthens our foundation for innovation and excellence as we continue to serve our clients with integrity and precision,” said John D. Balian, MD, CEO, ClinChoice International.
This accomplishment reaffirms ClinChoice’s dedication to upholding the highest international standards and delivering trusted, high-quality solutions to clients around the world.
About ClinChoice
ClinChoice is a leading global full & functional service CRO, renowned for its exceptional product development and lifecycle management capabilities across the pharmaceutical, biotechnology, medical device, and consumer health sectors. With three decades of proven expertise and outstanding results, we excel in delivering top-tier services.
Our deep regulatory expertise, clinical trial execution, and robust pharmacovigilance and biometrics capabilities position us as a trusted partner in global markets. ClinChoice proudly maintains a strong presence across the Americas, Europe, and Asia-Pacific, ensuring comprehensive support for our clients worldwide.